pubmed.ncbi.nlm.nih.gov

Superior palatability of crushed lercanidipine compared with amlodipine among children - PubMed

Randomized Controlled Trial

Superior palatability of crushed lercanidipine compared with amlodipine among children

Gregorio Milani et al. Br J Clin Pharmacol. 2010 Feb.

Abstract

Aims: To compare the taste of equivalent doses of pulverized amlodipine and lercanidipine, two calcium channel blockers, among children with kidney disease.

Methods: Each child received a test dose of 1 mg of amlodipine besylate and 2 mg of lercanidipine in a single-blinded fashion. Children indicated their preference by pointing to the appropriate face on a visual analogue scale (VAS) that depicts five degrees of pleasure.

Results: The VAS palatability score assigned to lercanidipine was higher than that assigned to amlodipine both in nine children 4-7 years of age (P < 0.005) and in 10 children 8-11 years of age (P < 0.005). The preference for lercanidipine was statistically significant in both girls (P < 0.02) and boys (P < 0.001) and in both children initially presented amlodipine (P < 0.005) and children initially presented lercanidipine (P < 0.005).

Conclusions: There is a lack of appropriate formulations for children prescribed drugs originally designed for adults, such as calcium channel blockers. Parents therefore crush available tablets and administer the medication mixed with solid food or a palatable drink. From the perspective of the child, the taste of pulverized lercanidipine is superior to that of pulverized amlodipine.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Visual analogue scale palatability score of pulverized amlodipine (1 mg) and pulverized lercanidipine (2 mg) in children with acute or chronic kidney disease. The palatability score assigned to lercanidipine was higher than that assigned to amlodipine in nine children 4–7 years old (P < 0.005), in 10 children 8–11 years old (P < 0.005) and in the cumulated group of 19 children 4–11 years old (P < 0.001)

Similar articles

Cited by

References

    1. Nayler WG. Amlodipine: an overview. Clin Drug Investig. 1997;13(Suppl 1):1–11.
    1. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8:357–73. - PubMed
    1. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag. 2005;1:173–82. - PMC - PubMed
    1. Pruijm MT, Maillard MP, Burnier M. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine. Vasc Health Risk Manag. 2008;4:1159–66. - PMC - PubMed
    1. Nunn AJ. Making medicines that children can take. Arch Dis Child. 2003;88:369–71. - PMC - PubMed

Publication types

MeSH terms

Substances